Destiny Pharma has won Deal of the Year at the Insider South East Dealmakers Awards 2018, held on 1 February 2018 at The Copthorne in Gatwick, UK.
Now in its twelfth year, the Dealmakers awards recognise the region’s top deals and advisory companies over the course of the last 12 months. The Deal of the Year award follows Destiny Pharma’s flotation on AIM in September 2017, raising £15.3m to accelerate the clinical development of its lead product, XF-73, and XF drug development platform.
Neil Clark, Chief Executive Officer of Destiny Pharma, commented:
“We are very pleased to be awarded this award for our successful placing and admission to trading on AIM in September of last year, which marked a major milestone for Destiny Pharma. We continue to advance the clinical development of our lead product, XF-73, and our proprietary XF drug development platform to offer a novel way of tackling the global problem of anti-microbial resistance.”